Advancing Critical Care |
INOMAX® is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.
INOMAX Important Safety Information (ISI)
INOMAX should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood
About Ikaria
Ikaria® is a biotherapeutics company whose goal is to provide acute care therapies addressing the significant unmet needs of critically ill patients. INOMAX® (nitric oxide) for inhalation is Ikaria’s flagship product. We are proud to have brought this important therapy to clinicians and patients in the U.S. since 1999.
